A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

Phase 1 Active not recruiting 179 enrolled Chugai Pharmaceutical

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, dose-escalation study designed to determine the maximum tolerated dose (MTD) by evaluating dose-limiting toxicities (DLTs) and to evaluate the safety, tolerability, pharmacokinetics, anti-tumor effect, and biomarkers of ERY974 in combination with atezolizumab and bevacizumab following premedication with tocilizumab in patients with locally advanced or metastatic HCC.

Timeline

Start: 2021-06-01
Primary completion: 2025-12-31
Completion: 2025-12-31

Publications

Komatsu SI, Kayukawa Y, Miyazaki Y, Kaneko A, Ikegami H, Ishiguro T, Nakamura M, Frings W, Ono N, Sakata K, Fujii T, Kishishita S, Kitazawa T, Endo M, Sano Y. Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial. Sci Rep. 2022 Jul 19;12(1):12312. doi: 10.1038/s41598-022-16564-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ERY974	Unknown	3 ng	Intravenous
Background	Atezolizumab	Monoclonal antibody	—	—
Background	Bevacizumab	Monoclonal antibody	—	—
Background	Tocilizumab	Monoclonal antibody	—	—

A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

Summary

Timeline

Publications

Drugs

Indications